Waystar (NASDAQ:WAY) vs. Firefly Neuroscience (NASDAQ:AIFF) Financial Analysis
by Amy Steele · The Cerbat GemFirefly Neuroscience (NASDAQ:AIFF – Get Free Report) and Waystar (NASDAQ:WAY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Institutional & Insider Ownership
5.0% of Firefly Neuroscience shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by insiders. Comparatively, 3.5% of Waystar shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
Firefly Neuroscience has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Waystar has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.
Valuation & Earnings
This table compares Firefly Neuroscience and Waystar”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Firefly Neuroscience | $1.80 million | 9.59 | -$19.88 million | ($0.63) | -1.75 |
| Waystar | $1.21 billion | 3.87 | $112.09 million | $0.70 | 34.76 |
Waystar has higher revenue and earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Waystar, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for Firefly Neuroscience and Waystar, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Firefly Neuroscience | 1 | 0 | 0 | 0 | 1.00 |
| Waystar | 1 | 2 | 18 | 3 | 2.96 |
Waystar has a consensus target price of $35.23, suggesting a potential upside of 44.78%. Given Waystar’s stronger consensus rating and higher probable upside, analysts plainly believe Waystar is more favorable than Firefly Neuroscience.
Profitability
This table compares Firefly Neuroscience and Waystar’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Firefly Neuroscience | -565.40% | -94.68% | -73.51% |
| Waystar | 11.18% | 7.03% | 4.75% |
Summary
Waystar beats Firefly Neuroscience on 11 of the 15 factors compared between the two stocks.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
About Waystar
Waystar Holding Corp. is a software company which provide healthcare payments. Waystar Holding Corp. is based in LEHI, Utah.